神经药理学报

神经药理学报 ›› 2024, Vol. 14 ›› Issue (6): 58-.DOI: 10.3969/j.issn.2095-1396.2024.06.009

• 综述 • 上一篇    

口服化疗药希罗达应用进展

贾晓坤   

  1. 张家口市中心血站体采科，张家口，075000，中国
  • 出版日期:2024-12-26 发布日期:2024-12-26
  • 作者简介:贾晓坤，副主任技师；研究方向：血液学、肿瘤学

Progress in the Use of Oral Chemotherapeutic Agent Xeloda

JIA Xiao-kun   

  1. The Department of Body Collection, Zhangjiakou Central Blood Station, Zhangjiakou, 075000, China
  • Online:2024-12-26 Published:2024-12-26

PDF (PC)

5

摘要：

希罗达，首款氟尿嘧啶类口服化疗药，通过肠吸收转化为5- 氟尿嘧啶(5-fluorouracil，5-FU），细胞代谢 5-FU 转化为脱氧尿苷酸单磷酸（deoxyfluorouracil monophosphate，FdUMP）和5- 氟尿苷三磷酸（fluorouracil uridine triphosphate，FUTP），能够很好的模拟5-FU 静脉注射治疗状态，有效性高，因其安全便利及高效，常以辅 助治疗用药或与紫杉醇等药物联合用药治疗乳腺癌、胃癌等疾病，但仍存在众多不良反应，该文就口服化疗药希 罗达的作用、临床效果等进行综述。

关键词: 希罗达, 药理作用, 药物代谢动力学, 临床应用

Abstract:

Xeloda, also known as capecitabine tablets, is the first oral fluorouracil chemotherapy drug, which is converted into 5-fluorouracil（5-FU） by intestinal absorption, and 5-FU is converted into deoxyuridylate monophosphate (FdUMP) and 5-fluoruridylate triphosphate (FUTP) by cell metabolism. It can well simulate the state of 5-FU intravenous therapy, with high effectiveness. Convenience and high efficiency are often used in adjuvant therapy, combined with paclitaxel and other drugs to treat breast cancer, gastric cancer and other diseases, but there are still many adverse reactions. This article reviews the structure, function, clinical application and clinical effect of oral chemotherapy Xeloda.

Key words: Xeloda, capecitabine, pharmacological effects, pharmacokinetics, clinical application

中图分类号: